Recommendation not to start new patients on Tredaptive (ER niacin/laropiprant, MSD) in light of results of HPS2-THRIVE cardiovascular outcomes study

MSD would like to inform healthcare professionals that the HPS2-THRIVE study of Tredaptive^TM did not meet its primary endpoint of reduction of major vascular events which included the combination of coronary deaths, non-fatal heart attacks, strokes or revascularisations. In addition, there was a statistically significant increase in the incidence of some types of non-fatal serious adverse events in the group that received Tredaptive^TM and statin compared to the group that received statin alone. Given the current understanding of these new data and until additional analyses can be completed, physicians are advised not to start new patients on Tredaptive^TM. It is not necessary at this time to stop Tredaptive^TM in patients who are currently using the therapy. Healthcare professionals will be updated when new information becomes available.

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of these letters can be found in the MOH Alert System, which is accessible via the Health Professionals Portal (HPP), a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://hpp.moh.gov.sg and follow the procedures below to access the MOH Alert system.

Step 1: Select your profession under ‘For Healthcare Professionals’.

Step 2: Click on ‘Useful links’.

Step 3: Click on ‘MOH Alert’ and log in via Singpass.

Step 4: Click on ‘Drug Alerts’ or ‘Med Device Alerts’ to view the DHCPLs.